Ayala Pharmaceuticals is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab). We show 7 historical shares outstanding datapoints in our AYLA shares outstanding history coverage, used to compute AYLA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AYLA market cap history over the course of time is important for investors
interested in comparing AYLA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AYLA versus a peer is one thing; comparing
AYLA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AYLA can fluctuate over the course of history.
With this page we aim to empower investors researching AYLA by allowing them to research the AYLA market cap history. |
Free AYLA Email Alerts:
Video: The Importance of Market Cap
